Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 127 |
| Updated: | 11/2/2018 |
| Start Date: | July 30, 2008 |
| End Date: | September 19, 2018 |
A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281
against liposomal doxorubicin to see which is effective and well tolerated in treating
patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed
previous platinum therapy.
against liposomal doxorubicin to see which is effective and well tolerated in treating
patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed
previous platinum therapy.
Inclusion Criteria:
- Advanced ovarian cancer with positive BRCA1 or BRCA2 status
- Progressive or recurrent disease after platinum-based chemotherapy
- Measurable disease by RECIST
Exclusion Criteria:
- Previous anthracycline treatment
- Brain metastases
- Less than 28 days since last treatment used to treat the disease
- Considered a poor medical risk due to a serious uncontrolled disorder
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials